Leap Therapeutics
eröffnet am 20.09.21 10:17:48 von
neuester Beitrag 25.01.23 10:41:10 von
neuester Beitrag 25.01.23 10:41:10 von
Beiträge: 8
ID: 1.352.651
ID: 1.352.651
Aufrufe heute: 0
Gesamt: 877
Gesamt: 877
Aktive User: 0
ISIN: US52187K1016 · WKN: A2DK5X · Symbol: LPTX
0,5221
USD
-23,22 %
-0,1579 USD
Letzter Kurs 21.06.23 Nasdaq
Neuigkeiten
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 3,7600 | +94,82 | |
| 1,7620 | +40,96 | |
| 1,2099 | +34,52 | |
| 1,7000 | +33,86 | |
| 0,9500 | +33,67 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2029 | -14,15 | |
| 1,6100 | -15,26 | |
| 5,8000 | -17,61 | |
| 3,5000 | -26,24 | |
| 11,500 | -29,23 |
Beitrag zu dieser Diskussion schreiben
Feedback
Leap Therapeutics Acquires Flame Biosciences
https://investors.leaptx.com/news-releases/news-release-deta…
https://investors.leaptx.com/news-releases/news-release-deta…
das Rückgrat im Kampf gegen Konkurenz
USE OF BETA -CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI- DKK- 1 ANTIBODYdas ist ein US Patent, klar, das von LPTX!
US 11,267,876 B2
neben einer Vielzahl von Aminosäureketten ist eben hier beschrieben was zum finanziellen Durchbruch reichen soll
https://patentimages.storage.googleapis.com/63/27/44/2016dfe…
weltweit ist diese Methode geschützt! WO2018081437A1
https://patentimages.storage.googleapis.com/ed/19/07/0cbd8a5…
die Grundlagen sind also vorhanden. nun muss sich der Erfolg einstellen? so tief bin ich noch nicht
die letzte Präsentation lässt für mich noch viele fragen offen, ich verstehe aktuell einfach noch nicht in welchen Stadium lptx zum finanziellen Erfolg steckt. Danke für Euren Input.
Interessantes Nugget auf Twitter, gefunden bei der PR zu Q1
https://twitter.com/srqstockpicker/status/152507651124142899…
Das könnte ein recht deutlicher Hinweis auf hohes mPFS und mOS sein, inkl. hoher Durability. Warum sonst hebt man die "Duration of patients on trial" hervor als Kostentreiber?
https://twitter.com/srqstockpicker/status/152507651124142899…
Das könnte ein recht deutlicher Hinweis auf hohes mPFS und mOS sein, inkl. hoher Durability. Warum sonst hebt man die "Duration of patients on trial" hervor als Kostentreiber?
Eli Lilly and Company kauft sich ein
Hallo zusammen,nun wird es interessant....
Eli Lilly and Company hat sich beteiligt... 3,15 Millionen Aktien.
https://newsfilter.io/a/d10b5cdaf6fe549fad7a6be41c3a6cf0
Vielleicht bekommen wir jetzt einen schönen Bieter-Wettbewerb...?
LIeben Gruß
Sven
Antwort auf Beitrag Nr.: 70.584.020 von morleidender am 20.01.22 22:12:15Die AEs sind in etwa vergleichbar mit der Kombination aus Chemo und PD1-Inhibitor, wenn ich das richtig gesehen habe. Von den drei Todesfällen (Grade 5 TEAE) werden zwei auf Disease Progression zurückgeführt.
Die Lungenembolie in einem Fall ist wohl auf die Therapie zurückzuführen.
Wird sich zeigen, wie die FDA das sieht. Ich bleibe dabei, die Ergebnisse sind gut
Die Lungenembolie in einem Fall ist wohl auf die Therapie zurückzuführen.
Wird sich zeigen, wie die FDA das sieht. Ich bleibe dabei, die Ergebnisse sind gut
Trading Spotlight
Antwort auf Beitrag Nr.: 70.558.103 von StellaVella am 19.01.22 11:11:20
ob die so gut waren? AEs doch recht ordentlich!
Zitat von StellaVella:
Gute Ergebnisse:
https://investors.leaptx.com/news-releases/news-release-deta…
First-Line Part A Key Findings
Overall preliminary median progression-free survival (PFS) was 10.7 months
o
PFS was longer in DKK1-high patients at 11.9 months, compared to 10.7 months in DKK1-low patients
Preliminary median duration of response (DoR) was 10.7 months in DKK1-high patients, compared to 7.9 months in DKK1-low patients
Median overall survival has not been reached
Among patients who received a full first cycle of DKN-01 (modified intent to treat, n=22), the objective response rate (ORR) was 68%, including one complete response (CR) and 14 partial responses (PR)
90% ORR in DKK1-high patients (n=10)
56% ORR in DKK1-low patients (n=9)
Activity was independent of PD-L1 expression
79% ORR in PD-L1-low (vCPS < 5) and 67% ORR in PD-L1-high (vCPS > 5) patients
100% ORR in DKK1-high, PD-L1-low patients (n=6)
Combination was well tolerated, safety profile consistent with previous update and reflecting the underlying patient population
Second-Line Part B Key Findings
DKN-01 and tislelizumab administered in DKK1-high, PD-1 naïve patients was well tolerated at both 300mg and 600mg DKN-01 doses
Among evaluable patients who received a full first cycle of DKN-01 (response evaluable modified intent to treat, n=20), the objective response rate (ORR) was 25%, including 5 PRs and 4 stable disease (SD). One additional patient has had an irPR by iRECIST criteria.
PD-L1 expression is low overall in the study population and not correlated with DKK1 expression
The study is ongoing and enrolling in the 600mg DKN-01 cohort. Twelve patients were on study at the time of the data cut, four of whom had not yet had their first imaging assessment.
Wird interessant, wie BeiGene weiter vorgeht.
ob die so gut waren? AEs doch recht ordentlich!
Gute Ergebnisse:
https://investors.leaptx.com/news-releases/news-release-deta…
First-Line Part A Key Findings
Overall preliminary median progression-free survival (PFS) was 10.7 months
PFS was longer in DKK1-high patients at 11.9 months, compared to 10.7 months in DKK1-low patients
Preliminary median duration of response (DoR) was 10.7 months in DKK1-high patients, compared to 7.9 months in DKK1-low patients
Median overall survival has not been reached
Among patients who received a full first cycle of DKN-01 (modified intent to treat, n=22), the objective response rate (ORR) was 68%, including one complete response (CR) and 14 partial responses (PR)
90% ORR in DKK1-high patients (n=10)
56% ORR in DKK1-low patients (n=9)
Activity was independent of PD-L1 expression
79% ORR in PD-L1-low (vCPS < 5) and 67% ORR in PD-L1-high (vCPS > 5) patients
100% ORR in DKK1-high, PD-L1-low patients (n=6)
Combination was well tolerated, safety profile consistent with previous update and reflecting the underlying patient population
Second-Line Part B Key Findings
DKN-01 and tislelizumab administered in DKK1-high, PD-1 naïve patients was well tolerated at both 300mg and 600mg DKN-01 doses
Among evaluable patients who received a full first cycle of DKN-01 (response evaluable modified intent to treat, n=20), the objective response rate (ORR) was 25%, including 5 PRs and 4 stable disease (SD). One additional patient has had an irPR by iRECIST criteria.
PD-L1 expression is low overall in the study population and not correlated with DKK1 expression
The study is ongoing and enrolling in the 600mg DKN-01 cohort. Twelve patients were on study at the time of the data cut, four of whom had not yet had their first imaging assessment.
Wird interessant, wie BeiGene weiter vorgeht.
https://investors.leaptx.com/news-releases/news-release-deta…
First-Line Part A Key Findings
Overall preliminary median progression-free survival (PFS) was 10.7 months
PFS was longer in DKK1-high patients at 11.9 months, compared to 10.7 months in DKK1-low patients
Preliminary median duration of response (DoR) was 10.7 months in DKK1-high patients, compared to 7.9 months in DKK1-low patients
Median overall survival has not been reached
Among patients who received a full first cycle of DKN-01 (modified intent to treat, n=22), the objective response rate (ORR) was 68%, including one complete response (CR) and 14 partial responses (PR)
90% ORR in DKK1-high patients (n=10)
56% ORR in DKK1-low patients (n=9)
Activity was independent of PD-L1 expression
79% ORR in PD-L1-low (vCPS < 5) and 67% ORR in PD-L1-high (vCPS > 5) patients
100% ORR in DKK1-high, PD-L1-low patients (n=6)
Combination was well tolerated, safety profile consistent with previous update and reflecting the underlying patient population
Second-Line Part B Key Findings
DKN-01 and tislelizumab administered in DKK1-high, PD-1 naïve patients was well tolerated at both 300mg and 600mg DKN-01 doses
Among evaluable patients who received a full first cycle of DKN-01 (response evaluable modified intent to treat, n=20), the objective response rate (ORR) was 25%, including 5 PRs and 4 stable disease (SD). One additional patient has had an irPR by iRECIST criteria.
PD-L1 expression is low overall in the study population and not correlated with DKK1 expression
The study is ongoing and enrolling in the 600mg DKN-01 cohort. Twelve patients were on study at the time of the data cut, four of whom had not yet had their first imaging assessment.
Wird interessant, wie BeiGene weiter vorgeht.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
https://investors.leaptx.com/news-releases/news-release-deta…
"Recommendations
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics to $5 from $4 and keeps an Overweight rating on the shares after the company held a conference call following data presented at ESMO from the DisTinGuish study in 1st-line G/GEJ cancer that featured two KOLs. Most notably, the KOLs viewed the cohort of patients to actually be enriched for non-responders and that DKN-01 + pembrolizumab maintenance should experience long-term tolerability, the analyst notes. This latter point, together with the waterfall plot could translate to favorable signals of durability, Catanzaro contends. The analyst also points out that additional data are expected in the first half of 2022 and will likely be followed by a database lock later in 2022, which will formally start the clock on BeiGene's Asia option decision"
https://thefly.com/news.php?symbol=LPTX
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand. For more information about Leap Therapeutics, visit http://www.leaptx.com
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
https://investors.leaptx.com/news-releases/news-release-deta…
"Recommendations
Piper Sandler keeps Overweight on Leap Therapeutics, ups target to $5
Piper Sandler analyst Joseph Catanzaro raised the firm's price target on Leap Therapeutics to $5 from $4 and keeps an Overweight rating on the shares after the company held a conference call following data presented at ESMO from the DisTinGuish study in 1st-line G/GEJ cancer that featured two KOLs. Most notably, the KOLs viewed the cohort of patients to actually be enriched for non-responders and that DKN-01 + pembrolizumab maintenance should experience long-term tolerability, the analyst notes. This latter point, together with the waterfall plot could translate to favorable signals of durability, Catanzaro contends. The analyst also points out that additional data are expected in the first half of 2022 and will likely be followed by a database lock later in 2022, which will formally start the clock on BeiGene's Asia option decision"
https://thefly.com/news.php?symbol=LPTX
DurchsuchenBeitrag schreiben
